Lista de obras - Wolfgang Hiddemann - Dominio Público Uruguay

2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma

artículo científico publicado en 2009

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

artículo científico publicado en 2008

Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia

artículo científico publicado en 2014

Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia

artículo científico publicado en 2006

Acute myeloid leukemia: treatment over 60.

artículo científico publicado en 2002

Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles

artículo científico publicado en 2002

Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group

artículo científico publicado en 2009

Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial

artículo científico publicado en 2011

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia

artículo científico publicado en 2008

An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging

artículo científico publicado en 2015

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

artículo científico publicado en 2002

CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells

artículo científico publicado en 2012

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

artículo científico publicado en 2016

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c

artículo científico publicado en 2006

Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia

artículo científico publicado en 2014

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

artículo científico publicado en 2010

Development and Evaluation of an Ethical Guideline for Decisions to Limit Life-Prolonging Treatment in Advanced Cancer: Protocol for a Monocentric Mixed-Method Interventional Study.

artículo científico publicado en 2018

Downregulation of c-Jun expression by transcription factor C/EBPalpha is critical for granulocytic lineage commitment

artículo científico publicado en 2002

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

artículo científico publicado en 2002

Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia

artículo científico publicado en 2004

FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia

artículo científico publicado en 2004

FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).

artículo científico publicado en 2005

FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.

artículo científico publicado en 2017

Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia

artículo científico publicado en 2002

Gene expression profiling as a tool for the diagnosis of acute leukemias ⬇️

artículo científico publicado el 1 de octubre de 2003

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).

artículo científico publicado en 2007

Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study

artículo científico publicado en 2013

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia

artículo científico publicado en 2015

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

artículo científico publicado en 2014

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

artículo científico publicado en 2015

Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification

artículo científico publicado en 2013

Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis

artículo científico

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

artículo científico publicado en 2007

Long-term follow-up of cytogenetically normal CEBPA-mutated AML

artículo científico publicado en 2014

Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation

artículo científico publicado en 2006

Mammalian WDR12 is a novel member of the Pes1-Bop1 complex and is required for ribosome biogenesis and cell proliferation

artículo científico publicado en 2005

Mantle cell lymphoma: Therapeutic strategies are different from CLL ⬇️

artículo científico publicado el 1 de junio de 2003

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

artículo científico publicado en 2009

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse

artículo científico publicado en 2014

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

artículo científico publicado en 2005

Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia.

artículo científico publicado en 2014

Proteome- and microarray-based expression analysis of lymphoma cell lines identifies a p53-centered cluster of differentially expressed proteins in mantle cell and follicular lymphoma.

artículo científico publicado en 2007

Proteomic analysis of transcription factor interactions in myeloid stem cell development and leukaemia

artículo científico publicado en 2002

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

artículo científico publicado en 2012

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

artículo científico publicado en 2003

Rituximab plus chemotherapy in follicular and mantle cell lymphomas

artículo científico publicado en 2003

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.

artículo científico publicado en 2016

Targeting CD157 in AML using a novel, Fc-engineered antibody construct

artículo científico publicado en 2017

The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice

artículo científico publicado en 2005

The NPM1 mutation type has no impact on survival in cytogenetically normal AML.

artículo científico publicado en 2014

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

artículo científico publicado en 2004

The clinical mutatome of core binding factor leukemia

scientific article published on 02 January 2020

The role of therapeutic leukapheresis in hyperleukocytotic AML.

artículo científico publicado en 2014

The vent-like homeobox gene VENTX promotes human myeloid differentiation and is highly expressed in acute myeloid leukemia ⬇️

artículo científico publicado en 2010

Validation of a Molecular Risk Score for Prognosis of Patients With Acute Promyelocytic Leukemia Treated With All-trans Retinoic Acid and Chemotherapy-containing Regimens

artículo científico publicado en 2017

What keeps oncologists from addressing palliative care early on with incurable cancer patients? An active stance seems key

artículo científico publicado en 2014

Lista de obras de Wolfgang Hiddemann

2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia

Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia

Acute myeloid leukemia: treatment over 60.

Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles

Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group

Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia

An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c

Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

Development and Evaluation of an Ethical Guideline for Decisions to Limit Life-Prolonging Treatment in Advanced Cancer: Protocol for a Monocentric Mixed-Method Interventional Study.

Downregulation of c-Jun expression by transcription factor C/EBPalpha is critical for granulocytic lineage commitment

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia

FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia

FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).

FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.

Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia

Gene expression profiling as a tool for the diagnosis of acute leukemias ⬇️

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).

Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification

Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

Long-term follow-up of cytogenetically normal CEBPA-mutated AML

Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation

Mammalian WDR12 is a novel member of the Pes1-Bop1 complex and is required for ribosome biogenesis and cell proliferation

Mantle cell lymphoma: Therapeutic strategies are different from CLL ⬇️

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia.

Proteome- and microarray-based expression analysis of lymphoma cell lines identifies a p53-centered cluster of differentially expressed proteins in mantle cell and follicular lymphoma.

Proteomic analysis of transcription factor interactions in myeloid stem cell development and leukaemia

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Rituximab plus chemotherapy in follicular and mantle cell lymphomas

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.

Targeting CD157 in AML using a novel, Fc-engineered antibody construct

The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice

The NPM1 mutation type has no impact on survival in cytogenetically normal AML.

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

The clinical mutatome of core binding factor leukemia

The role of therapeutic leukapheresis in hyperleukocytotic AML.

The vent-like homeobox gene VENTX promotes human myeloid differentiation and is highly expressed in acute myeloid leukemia ⬇️

Validation of a Molecular Risk Score for Prognosis of Patients With Acute Promyelocytic Leukemia Treated With All-trans Retinoic Acid and Chemotherapy-containing Regimens

What keeps oncologists from addressing palliative care early on with incurable cancer patients? An active stance seems key